References
- National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual. Manchester, UK; 2014.
- National Institute for Health and Care Excellence. Appraising Life-Extending, End of Life Treatments. Manchester, UK; 2009.
- Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19: Partitioned Suvival Analysis for Decision Modelling in Health Care: A Critical Review. Sheffield, UK: NICE Decision Support Unit Methods Development; 2017.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
- National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. Manchester, UK; 2013.
- Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6S):75s–80s. doi:10.1200/JOP.2011.00046923598848
- Nonzee NJ, Dandade NA, Patel U, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008;113(6):1446–1452. doi:10.1002/cncr.2371418683883
- Davis S. Assessing Technologies that are Not Cost-Effective at a Zero Price. Sheffield, UK: NICE Decision Support Unit Methods Development; 2014.
- National Institute for Health and Care Excellence. Consultation paper – Value based assessment of health technologies; 2014.
- Rowen D, Brazier J, Muluria C, et al. Eliciting societal preferences for weighting QALYs for burden of illness and end of life. Med Decis Making. 2016;36(2):210–222. doi:10.1177/0272989X1561938926670663
- Merck Sharp & Dohme. Pembrolizumab for treating advanced or recurrent PD-L1 positive non-small-cell lung cancer after progression with platinum-based chemotherapy [ID840]: evidence submission. TA428. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy [ID840]: Committee Papers: National Institute for Health and Care Excellence; 2016.
- Pfizer Ltd. Crizotinib for the first-line treatment of anaplastic lymphoma kinase-positive, advanced non-small-cell lung cancer [ID865]: company evidence submission. TA406. Crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865]: Committee Papers: National Institute for Health and Care Excellence; 2016.